{"protocolSection": {"identificationModule": {"nctId": "NCT03364608", "orgStudyIdInfo": {"id": "D6930C00001"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Compare PT007 to Placebo MDI and Open-Label Proventil\u00ae HFA in Adult and Adolescent Subjects With Asthma", "officialTitle": "A Randomized, Double-blind, Single Dose, Placebo-controlled, 5-Period, 5-Treatment, Crossover, Multi-center, Dose-ranging Study to Compare PT007 to Placebo MDI and Open-Label Proventil\u00ae HFA in Adult and Adolescent Subjects With Mild to Moderate Asthma (ANTORA)"}, "statusModule": {"statusVerifiedDate": "2019-07", "overallStatus": "COMPLETED", "startDateStruct": {"date": "2017-12-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-03-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-03-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-12-01", "studyFirstSubmitQcDate": "2017-12-01", "studyFirstPostDateStruct": {"date": "2017-12-06", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2019-03-29", "resultsFirstSubmitQcDate": "2019-07-23", "resultsFirstPostDateStruct": {"date": "2019-07-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-07-23", "lastUpdatePostDateStruct": {"date": "2019-07-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS MDI), 90 \u03bcg and 180 \u03bcg, compared with placebo for AS MDI (hereafter referred to as Placebo MDI) and open-label Proventil\u00ae hydrofluoroalkane (HFA; hereafter referred to as Proventil) 90 \u03bcg and 180 \u03bcg in adult and adolescent subjects with mild to moderate asthma. This study design utilizes 10 treatment sequences.", "detailedDescription": "This is a 5-period crossover study. Each Treatment Period is 1 day. Subjects will receive a single dose of randomized study drug at each of the 5 Treatment Visits (Visits 2, 3, 4, 5, and 6), with a 3- to 7-day Washout Period between Treatment Visits."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 86, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "\u2022 AS MDI 90 \u00b5g", "type": "EXPERIMENTAL", "description": "(2 actuations of 45 \u00b5g/actuation)", "interventionNames": ["Drug: AS MDI 90 \u03bcg"]}, {"label": "\u2022 AS MDI 180 \u00b5g", "type": "EXPERIMENTAL", "description": "(2 actuations of 90 \u00b5g/actuation)", "interventionNames": ["Drug: AS MDI 180 \u00b5g"]}, {"label": "\u2022 Placebo MDI", "type": "PLACEBO_COMPARATOR", "description": "(2 actuations)", "interventionNames": ["Other: Placebo MDI"]}, {"label": "\u2022 Proventil 90 \u00b5g", "type": "ACTIVE_COMPARATOR", "description": "(1 actuation of 90 \u00b5g/actuation)", "interventionNames": ["Drug: Proventil 90 \u03bcg"]}, {"label": "\u2022 Proventil 180 \u00b5g", "type": "ACTIVE_COMPARATOR", "description": "(2 actuations of 90 \u00b5g/actuation)", "interventionNames": ["Drug: Proventil 180 \u03bcg"]}], "interventions": [{"type": "DRUG", "name": "AS MDI 90 \u03bcg", "description": "AS MDI 90 \u03bcg (2 actuations of 45 \u03bcg/actuation)", "armGroupLabels": ["\u2022 AS MDI 90 \u00b5g"], "otherNames": ["AS MDI"]}, {"type": "DRUG", "name": "AS MDI 180 \u00b5g", "description": "AS MDI 180 \u03bcg (2 actuations of 90 \u03bcg/actuation)", "armGroupLabels": ["\u2022 AS MDI 180 \u00b5g"], "otherNames": ["AS MDI"]}, {"type": "OTHER", "name": "Placebo MDI", "description": "Placebo MDI (2 actuations)", "armGroupLabels": ["\u2022 Placebo MDI"]}, {"type": "DRUG", "name": "Proventil 90 \u03bcg", "description": "Proventil 90 \u03bcg (1 actuation of 90 \u03bcg/actuation)", "armGroupLabels": ["\u2022 Proventil 90 \u00b5g"], "otherNames": ["Proventil"]}, {"type": "DRUG", "name": "Proventil 180 \u03bcg", "description": "Proventil 180 \u03bcg (2 actuations of 90 \u03bcg/actuation)", "armGroupLabels": ["\u2022 Proventil 180 \u00b5g"], "otherNames": ["Proventil"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in FEV1 AUC0-6", "description": "Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-6 (Area under the curve from 0 to 6 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes post-dose) normalized for length of follow up.", "timeFrame": "Over 6 hours post dose on Day 1"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FEV1 AUC0-4", "description": "Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-4 (Area under the curve from 0 to 4 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, and 240 minutes post-dose) normalized for length of follow up.", "timeFrame": "Over 4 hours post dose on Day 1"}, {"measure": "Peak Change From Baseline in FEV1", "description": "Peak Change from baseline in FEV1 (Forced expiratory volume in 1 second)", "timeFrame": "Over 6 hours post dose on Day 1"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* Are at least 12 years of age and no older than 65 years\n* Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis\n* Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy\n* Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society \\[ATS\\]/European Respiratory Society \\[ERS\\] acceptability/repeatability criteria\n* Pre-bronchodilator FEV1 of \u226540 to \\<90% predicted normal value after withholding SABA for \u22656 hours\n* Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1 of \u226515%\n* only 2 reversibility testing attempts are allowed\n\nExclusion Criteria:\n\n* Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)\n* Oral corticosteroid use (any dose) within 6 weeks\n* Current smokers, former smokers with \\>10 pack-years history, or former smokers who stopped smoking \\<6 months (including all forms of tobacco, e-cigarettes \\[vaping\\], and marijuana)\n* Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)\n* Historical or current evidence of a clinically significant disease\n* Cancer not in complete remission for at least 5 years\n* Hospitalized for psychiatric disorder or attempted suicide within 1 year\n* Unable to abstain from protocol-defined prohibited medications during the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}]}, "referencesModule": {"references": [{"pmid": "34089147", "type": "DERIVED", "citation": "Cappelletti C, Maes A, Rossman K, Gillen M, LaForce C, Kerwin EM, Reisner C. Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials. Clin Drug Investig. 2021 Jun;41(6):579-590. doi: 10.1007/s40261-021-01040-7. Epub 2021 Jun 4."}], "seeAlsoLinks": [{"label": "Protocol", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=14724&filename=PT007001_Protocol_Redacted_PDFA.pdf"}, {"label": "Statistical Analysis Plan (SAP)", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=14724&filename=PT007001_SAP_Redacted_PDFA.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects were randomized into one of 10 treatment sequences. Each sequence comprised all 5 treatments included in this study (ie, AS MDI 90 \u03bcg, AS MDI 180 \u03bcg, Placebo MDI, Proventil 90 \u03bcg, and Proventil 180 \u03bcg) in a randomized order", "recruitmentDetails": "This study was conducted at 10 sites in the United States, from December 2017 to March 2018. The study was anticipated to run for at least 23 days but not to exceed 68 days.", "groups": [{"id": "FG000", "title": "Subjects", "description": "ITT Analysis set"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "ITT Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "86"}]}, {"type": "Placebo MDI", "comment": "(2 actuations)", "achievements": [{"groupId": "FG000", "numSubjects": "82"}]}, {"type": "AS MDI 90 \u00b5g", "comment": "(2 actuations of 45 \u00b5g/actuation)", "achievements": [{"groupId": "FG000", "numSubjects": "81"}]}, {"type": "AS MDI 180 \u00b5g", "comment": "(2 actuations of 90 \u00b5g/actuation)", "achievements": [{"groupId": "FG000", "numSubjects": "81"}]}, {"type": "Proventil 90 \u00b5g", "comment": "(1 actuation of 90 \u00b5g/actuation)", "achievements": [{"groupId": "FG000", "numSubjects": "82"}]}, {"type": "Proventil 180 \u00b5g", "comment": "(2 actuations of 90 \u00b5g/actuation)", "achievements": [{"groupId": "FG000", "numSubjects": "79"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Overall number of Baseline Participants is from the Safety set.", "groups": [{"id": "BG000", "title": "Overall Study", "description": "Safety Set"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "86"}]}], "measures": [{"title": "Age, Continuous", "populationDescription": "Safety Set", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.7", "spread": "13.4"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "Safety Set", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "47"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "39"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "populationDescription": "Safety Set", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "14"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "72"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "populationDescription": "Safety Set", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "62"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in FEV1 AUC0-6", "description": "Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-6 (Area under the curve from 0 to 6 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes post-dose) normalized for length of follow up.", "populationDescription": "mITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Over 6 hours post dose on Day 1", "groups": [{"id": "OG000", "title": "AS MDI 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)"}, {"id": "OG001", "title": "AS MDI 90 \u00b5g", "description": "(2 actuations of 45 \u00b5g/actuation)"}, {"id": "OG002", "title": "Proventil 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)"}, {"id": "OG003", "title": "Proventil 90 \u00b5g", "description": "(1 actuation of 90 \u00b5g/actuation)"}, {"id": "OG004", "title": "Placebo MDI", "description": "(2 actuations)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "77"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.266", "lowerLimit": "0.219", "upperLimit": "0.313"}, {"groupId": "OG001", "value": "0.203", "lowerLimit": "0.156", "upperLimit": "0.251"}, {"groupId": "OG002", "value": "0.282", "lowerLimit": "0.234", "upperLimit": "0.329"}, {"groupId": "OG003", "value": "0.240", "lowerLimit": "0.193", "upperLimit": "0.288"}, {"groupId": "OG004", "value": "0.070", "lowerLimit": "0.022", "upperLimit": "0.117"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in FEV1 AUC0-4", "description": "Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-4 (Area under the curve from 0 to 4 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, and 240 minutes post-dose) normalized for length of follow up.", "populationDescription": "mITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Over 4 hours post dose on Day 1", "groups": [{"id": "OG000", "title": "AS MDI 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)"}, {"id": "OG001", "title": "AS MDI 90 \u00b5g", "description": "(2 actuations of 45 \u00b5g/actuation)"}, {"id": "OG002", "title": "Proventil 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)"}, {"id": "OG003", "title": "Proventil 90 \u00b5g", "description": "(1 actuation of 90 \u00b5g/actuation)"}, {"id": "OG004", "title": "Placebo MDI", "description": "(2 actuations)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "77"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.331", "lowerLimit": "0.280", "upperLimit": "0.381"}, {"groupId": "OG001", "value": "0.263", "lowerLimit": "0.213", "upperLimit": "0.313"}, {"groupId": "OG002", "value": "0.349", "lowerLimit": "0.299", "upperLimit": "0.400"}, {"groupId": "OG003", "value": "0.297", "lowerLimit": "0.247", "upperLimit": "0.348"}, {"groupId": "OG004", "value": "0.080", "lowerLimit": "0.030", "upperLimit": "0.131"}]}]}]}, {"type": "SECONDARY", "title": "Peak Change From Baseline in FEV1", "description": "Peak Change from baseline in FEV1 (Forced expiratory volume in 1 second)", "populationDescription": "mITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Over 6 hours post dose on Day 1", "groups": [{"id": "OG000", "title": "AS MDI 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)"}, {"id": "OG001", "title": "AS MDI 90 \u00b5g", "description": "(2 actuations of 45 \u00b5g/actuation)"}, {"id": "OG002", "title": "Proventil 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)"}, {"id": "OG003", "title": "Proventil 90 \u00b5g", "description": "(1 actuation of 90 \u00b5g/actuation)"}, {"id": "OG004", "title": "Placebo MDI", "description": "(2 actuations)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "77"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.509", "lowerLimit": "0.451", "upperLimit": "0.567"}, {"groupId": "OG001", "value": "0.433", "lowerLimit": "0.375", "upperLimit": "0.491"}, {"groupId": "OG002", "value": "0.516", "lowerLimit": "0.458", "upperLimit": "0.574"}, {"groupId": "OG003", "value": "0.472", "lowerLimit": "0.414", "upperLimit": "0.530"}, {"groupId": "OG004", "value": "0.233", "lowerLimit": "0.176", "upperLimit": "0.291"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Adverse events were collected from the time the subject signed informed consent throughout the treatment period and up to 14 days following the last dose of study drug", "description": "Serious Adverse Events were collected from the time the subject signed informed consent throughout the treatment period and up to approximately 68 days, which includes screening and follow up (3-7 days after last dose of study drug).", "eventGroups": [{"id": "EG000", "title": "Placebo MDI", "description": "(2 actuations)", "deathsNumAffected": 0, "deathsNumAtRisk": 82, "seriousNumAffected": 0, "seriousNumAtRisk": 82, "otherNumAffected": 0, "otherNumAtRisk": 82}, {"id": "EG001", "title": "AS MDI 90 \u00b5g", "description": "(2 actuations of 45 \u00b5g/actuation)", "deathsNumAffected": 0, "deathsNumAtRisk": 81, "seriousNumAffected": 0, "seriousNumAtRisk": 81, "otherNumAffected": 0, "otherNumAtRisk": 81}, {"id": "EG002", "title": "Proventil 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)", "deathsNumAffected": 0, "deathsNumAtRisk": 81, "seriousNumAffected": 0, "seriousNumAtRisk": 81, "otherNumAffected": 0, "otherNumAtRisk": 81}, {"id": "EG003", "title": "Proventil 90 \u00b5g", "description": "(1 actuation of 90 \u00b5g/actuation)", "deathsNumAffected": 0, "deathsNumAtRisk": 82, "seriousNumAffected": 0, "seriousNumAtRisk": 82, "otherNumAffected": 0, "otherNumAtRisk": 82}, {"id": "EG004", "title": "\u2022 Proventil 180 \u00b5g", "description": "(2 actuations of 90 \u00b5g/actuation)", "deathsNumAffected": 0, "deathsNumAtRisk": 79, "seriousNumAffected": 0, "seriousNumAtRisk": 79, "otherNumAffected": 0, "otherNumAtRisk": 79}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication."}, "pointOfContact": {"title": "Colin Reisner, MD FCCP, FAAAAI", "organization": "Pearl Therapeutics, Inc, a Member of the AstraZeneca Group", "email": "Colin.Reisner@astrazeneca.com", "phone": "9739750321"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-01-12", "uploadDate": "2019-03-29T04:54", "filename": "Prot_000.pdf", "size": 7760567}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-03-13", "uploadDate": "2019-03-29T04:54", "filename": "SAP_001.pdf", "size": 2611886}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "CNI", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}